2024-03-29T08:59:21Zhttp://repisalud.isciii.es/oai/requestoai:repisalud.isciii.es:20.500.12105/141122022-11-03T14:41:45Zcom_20.500.12105_15322com_20.500.12105_2051com_20.500.12105_2053com_20.500.12105_2052col_20.500.12105_16961col_20.500.12105_2054
Repisalud
author
May, Margaret T
author
Vehreschild, Jorg-Janne
author
Trickey, Adam
author
Obel, Niels
author
Reiss, Peter
author
Bonnet, Fabrice
author
Mary-Krause, Murielle
author
Samji, Hasina
author
Cavassini, Matthias
author
Gill, Michael John
author
Shepherd, Leah C
author
Crane, Heidi M
author
d'Arminio Monforte, Antonella
author
Burkholder, Greer A
author
Johnson, Margaret M
author
Sobrino-Vegas, Paz
author
Domingo, Pere
author
Zangerle, Robert
author
Justice, Amy C
author
Sterling, Timothy R
author
Miró, José M
author
Sterne, Jonathan A C
author
Antiretroviral Therapy Cohort Collaboration (ART-CC)
funder
Medical Research Council (Reino Unido)
funder
Department for International Development (Reino Unido)
funder
National Institute for Health Research (Reino Unido)
funder
Agence Nationale de Recherches sur le sida et les hépatites virales (Francia)
funder
Institut National de la Santé et de la Recherche Médicale (Francia)
funder
Ministère de la Santé (Francia)
funder
Ministero della Salute (Italia)
funder
Ministerio de Sanidad (España)
funder
Swiss National Science Foundation
funder
Ministerio de Ciencia e Innovación (España)
funder
Red de Investigación Cooperativa en Investigación en Sida (España)
funder
Stichting HIV Monitoring (Netherlands)
funder
Unión Europea
funder
National Institutes of Health (Estados Unidos)
funder
NIH - National Institute on Alcohol Abuse and Alcoholism (NIAAA) (Estados Unidos)
funder
United States Department of Veterans Affairs
funder
Michael Smith Foundation for Health Research
funder
Canadian Institutes of Health Research
funder
Veterans Health Administration
funder
Unión Europea. Comisión Europea. 7 Programa Marco
funder
Government of Alberta (Canadá)
funder
Government of Columnia (Estados Unidos)
funder
Government of the United Kingdom
funder
Abbott
funder
Gilead Sciences (Spain)
funder
Tibotec-Upjohn
funder
ViiV Healthcare
funder
GlaxoSmithKline
funder
Pfizer
funder
Bristol-Myers Squibb
funder
Roche
funder
Boehringer Ingelheim Fonds
funder
Merck, Sharp & Dohme
2022-04-19T12:35:22Z
2022-04-19T12:35:22Z
2016-06-15
Clin Infect Dis. 2016;62(12):1571-1577
http://hdl.handle.net/20.500.12105/14112
27025828
10.1093/cid/ciw183
1537-6591
Clinical Infectious Diseases: an official publication of the Infectious Diseases Society of America
Background. CD4 count at start of combination antiretroviral therapy (ART) is strongly associated with short-term survival, but its association with longer-term survival is less well characterized. Methods. We estimated mortality rates (MRs) by time since start of ART (<0.5, 0.5-0.9, 1-2.9, 3-4.9, 5-9.9, and ≥10 years) among patients from 18 European and North American cohorts who started ART during 1996-2001. Piecewise exponential models stratified by cohort were used to estimate crude and adjusted (for sex, age, transmission risk, period of starting ART [1996-1997, 1998-1999, 2000-2001], and AIDS and human immunodeficiency virus type 1 RNA at baseline) mortality rate ratios (MRRs) by CD4 count at start of ART (0-49, 50-99, 100-199, 200-349, 350-499, ≥500 cells/µL) overall and separately according to time since start of ART. Results. A total of 6344 of 37 496 patients died during 359 219 years of follow-up. The MR per 1000 person-years was 32.8 (95% confidence interval [CI], 30.2-35.5) during the first 6 months, declining to 16.0 (95% CI, 15.4-16.8) during 5-9.9 years and 14.2 (95% CI, 13.3-15.1) after 10 years' duration of ART. During the first year of ART, there was a strong inverse association of CD4 count at start of ART with mortality. This diminished over the next 4 years. The adjusted MRR per CD4 group was 0.97 (95% CI, .94-1.00; P = .054) and 1.02 (95% CI, .98-1.07; P = .32) among patients followed for 5-9.9 and ≥10 years, respectively. Conclusions. After surviving 5 years of ART, the mortality of patients who started ART with low baseline CD4 count converged with mortality of patients with intermediate and high baseline CD4 counts.
eng
CD4 count
HIV
Antiretroviral therapy
Cohort collaboration
Mortality
Mortality According to CD4 Count at Start of Combination Antiretroviral Therapy Among HIV-infected Patients Followed for up to 15 Years After Start of Treatment: Collaborative Cohort Study
journal article
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
URL
https://repisalud.isciii.es/bitstream/20.500.12105/14112/1/MortalityAccordingToCD4_2016.pdf
File
MD5
9d3aeb33be275588042ba52f6f0dacc1
279673
application/pdf
MortalityAccordingToCD4_2016.pdf
URL
https://repisalud.isciii.es/bitstream/20.500.12105/14112/2/MortalityAccordingToCD4SupplementaryData_2016.docx
File
MD5
2abbda23eec441743c389a62dc035176
24792
application/vnd.openxmlformats-officedocument.wordprocessingml.document
MortalityAccordingToCD4SupplementaryData_2016.docx
URL
https://repisalud.isciii.es/bitstream/20.500.12105/14112/5/MortalityAccordingToCD4_2016.pdf.txt
File
MD5
944c33edb08629c8f9b8e015f18c4390
41725
text/plain
MortalityAccordingToCD4_2016.pdf.txt